The idiopathic pulmonary fibrosis treatment market size is forecasted to increase by $1.361B from 2022 to 2027, accelerating at a CAGR of 6.68%, according to a study by Technavio. The growth will be driven by the increasing prevalence of respiratory diseases, the growing geriatric population, and the increase in the number of smokers.
Idiopathic pulmonary fibrosis is a fatal lung disease that affects thousands of people across the world. Exposure to occupational and environmental hazards, such as asbestos, silica, and metal dust particles, has increased the prevalence of the condition. The number of people diagnosed with IPF is increasing among all age groups and genders. The high prevalence of the condition has become a serious concern among healthcare providers and researchers. The prevalence of the condition is high among the aging population. If left untreated, IPF can result in disability, reduced productivity, and early retirement, leading to economic losses for individuals. All these factors are driving the growth of the market.
The global idiopathic pulmonary fibrosis (IPF) market is fragmented. The market has several approved drugs for the symptomatic treatment of IPF. Owing to the strong prevalence of IPF and the need for highly effective drugs, several vendors are developing drugs to treat IPF. The strong pipeline of novel drugs and therapeutics is expected to pave the way for new entrants in the market during the forecast period. Hence, the market is expected to witness the launch of various novel drugs and therapeutics and the entry of a few new players during the forecast period.